‘Life-Altering’: FDA Approves Pancreatic Cancer Drug
The daily pill nearly doubled median survival in a 500-patient study and was approved more than six months ahead of schedule.
- On Wednesday, August 26, 2026, the U.S. Food and Drug Administration approved daraxonrasib, a first-of-its-kind oral pill manufactured by Revolution Medicines and sold as Rasonque for advanced pancreatic cancer.
- The medication targets KRAS mutations fueling tumor growth in more than 90% of pancreatic cancer cases, using molecular glue technology to bind proteins previously considered 'undruggable' by researchers.
- In clinical trials, patients taking the pill lived for a median of more than 13 months compared with less than seven months on chemotherapy. Common side effects included rash and nausea.
- A one-month supply costs approximately $39,800. Seven patients at St. Charles Cancer Institute in Bend, Ore., began receiving daraxonrasib earlier this month, including La Pine resident John Johnson, who had exhausted other treatment options.
- Acting FDA Commissioner Kyle Diamantas called the approval a 'critical new option' for patients facing this deadly cancer. Doctors hope the drug's success opens doors for therapies targeting other cancers, with public attention amplified by former Nebraska U.S. Sen. Ben Sasse's public statements about pain relief.
22 Articles
22 Articles
The US Food and Drug Administration (FDA) approved a treatment for pancreatic cancer which, in clinical trials, almost doubled the total patient survival time, writes the BBC.
FDA approves Rasonque for advanced pancreatic cancer patients in the US
BATON ROUGE — The FDA has approved a new drug for patients with advanced pancreatic cancer, with doctors calling it a turning point in treating the disease.The once-daily oral pill, called Rasonque, is approved for metastatic pancreatic cancer patients who haven't found success with prior treatment and those who aren't able to receive traditional therapies."This is a new hope and it's a meaningful hope," Dr. Shafia Rahman of The Ohio State Unive…
The Oregonian
FDA approves breakthrough cancer drug months ahead of schedule: ‘Unprecedented results’
The U.S. Food and Drug Administration has approved a breakthrough drug for the most common form of pancreatic cancer more than six months ahead of schedule, offering what officials described as unprecedented survival rates for patients with limited options.
FDA approves first-of-its-kind pill for advanced pancreatic cancer six months early
By Rajwa Quasim The Food and Drug Administration (FDA) gave expedited approval this week to a first-of-its-kind pill for advanced pancreatic cancer, one of the deadliest forms of cancer. FDA regulators said Wednesday that the drug was approved more than six months ahead of schedule. The approved drug, daraxonrasib, will be sold under the brand name Rasonque by Revolution Medicines. The drug targets a mutated protein responsible for driving tumor…
St. Charles Offers Groundbreaking Pancreatic Cancer Medication
Patients at St. Charles Cancer Institute are receiving a ‘game changing’ medication found to double life expectancy for patients with stage 4 metastatic pancreatic cancer. Seven patients with St. Charles began receiving the medication daraxonrasib earlier this month, through expanded access that allows access to prescription drugs prior to approval from the Food and Drug Administration (FDA). The medication was approved by the FDA Aug. 26. While…
Coverage Details
Bias Distribution
- 62% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
